Lumigan (bimatoprost) is licensed for the reduction of elevated intraocular pressure in open-angle glaucoma and ocular hypertension, and FDA and MHRA-licensed generic bimatoprost eye drops now sit alongside the originator brand on hospital and retail formularies.
M Care Exports supplies Lumigan (bimatoprost), a synthetic prostamide originated by Allergan and now marketed by AbbVie, alongside FDA- and MHRA-licensed generic bimatoprost ophthalmic solution. It is dosed once daily to lower intraocular pressure in open-angle glaucoma and ocular hypertension, a chronic, lifelong therapy rather than a short course. M Care is a merchant exporter: we source Lumigan and generic bimatoprost through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Bimatoprost exporter and bulk supplier from India.
For hospital ophthalmology pharmacy, wholesaler and retail-chain orders, M Care quotes bimatoprost against buyer specification: brand (Lumigan) or generic, 0.03% or 0.01% concentration, and destination-market regulatory documentation. Because the two strengths are not interchangeable drop-for-drop across every destination label and multiple-eye-drop regimens need a five-minute dosing gap per the SmPC, we confirm the buyer's intended formulary placement and patient information leaflet before dispatch, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Synthetic prostamide analogue; prostaglandin F2-alpha structural analogue, sourced and documented for export.
Bimatoprost is a synthetic prostamide, structurally related to prostaglandin F2-alpha, that lowers intraocular pressure by increasing aqueous humour outflow through both the trabecular meshwork and the uveoscleral pathway. It is dosed as a topical eye drop, not injected, and needs no reconstitution or cold chain. Both the FDA label and the UK/EU SmPC restrict the licensed indication to reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, dosed as one drop in the affected eye once daily in the evening; more frequent dosing has been shown to lessen the pressure-lowering effect rather than improve it. Lumigan is supplied as 0.03% and 0.01% ophthalmic solution (0.3 mg/mL and 0.1 mg/mL bimatoprost respectively), each in a preservative-containing multidose dropper bottle.
Active ingredient
Bimatoprost. Synthetic prostamide analogue; prostaglandin F2-alpha structural analogue.
Forms and strengths
0.03 % (0.3 mg/mL) ophthalmic solution; 0.01 % (0.1 mg/mL) ophthalmic solution.
Indications
Bimatoprost, synthetic prostamide indicated for reduction of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Supplied as originator Lumigan and licensed generic eye drops from Indian WHO-GMP facilities to regulated and semi-regulated markets outside India.
Administration
Ophthalmic (topical eye drop). Ophthalmic solution (eye drops).
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for bimatoprost are hospital and community ophthalmology pharmacies managing chronic open-angle glaucoma and ocular hypertension caseloads, national and regional MoH tender desks running ophthalmic and chronic-disease formulary lists, licensed pharmaceutical wholesalers and importers, and retail pharmacy chains across our GCC and African markets stocking a glaucoma line where local scheduling and registration permit. Bimatoprost is a long-term, repeat-dispensing therapy, so tender desks typically specify a 12-month or multi-year supply commitment rather than a one-off order.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on bimatoprost.
Bimatoprost is dosed once daily in the evening; more frequent administration lessens rather than improves the intraocular pressure effect, so dosing counselling at dispensing matters more than with most drops. When a patient uses more than one topical ophthalmic product, space applications at least five minutes apart to avoid one drop washing out the other. There is no reconstitution, no admixture and no cold-chain requirement: the eye drops are dispensed ready to use and store at room temperature, with a four-week in-use discard period after opening per the UK SmPC even though the sealed bottle carries a longer shelf life. Counsel patients on permanent iris darkening and reversible eyelash and periorbital-tissue pigmentation changes, which are expected with long-term use and should be flagged before therapy starts, particularly where the patient has one treated and one untreated eye. Safety and efficacy in children and adolescents under 18 years have not been established per the UK SmPC, so paediatric use sits outside the licensed population. There is no boxed warning and bimatoprost is not a controlled substance in the markets M Care currently reviews.
The documentation pack a regulator actually asks for.
As a topical ophthalmic solution, bimatoprost travels on standard ambient-temperature logistics rather than the validated cold-chain lanes M Care runs for biologics and insulins. What buyers need instead is batch-level certificate of analysis, CDSCO export documentation and, where the destination market requires it, CTD or eCTD-format dossier support so the buyer's own regulator can register the product; the UK SmPC gives an unopened shelf life of two years with a four-week in-use limit once a bottle is opened. Bimatoprost does not appear on the WHO Model List of Essential Medicines; timolol is the topical antiglaucoma agent WHO lists in that category, so buyers should treat bimatoprost as a formulary-specific prostamide option rather than an EML first-line glaucoma drop when building a tender specification. On the brand-versus-generic question, Lumigan remains the originator product, developed by Allergan and now marketed by AbbVie; FDA-approved generic bimatoprost ophthalmic solution in both 0.03% and 0.01% concentrations is separately registered and marketed in the US from multiple manufacturers, and licensed generic bimatoprost eye drops are also available in the UK and EU. Buyers genuinely have a brand-or-generic choice on formulary; M Care quotes either against the tender specification and destination-market registration status. Allergan also markets a fixed-dose bimatoprost/timolol combination as Ganfort for patients not controlled on monotherapy, and a 0.03% bimatoprost solution as Latisse for eyelash hypotrichosis, a separate licensed indication from the glaucoma product; buyers should specify which product and indication they are tendering for, since pack size and patient information differ. Bimatoprost is not a controlled substance in the markets we currently review.
For the import route itself, step by step from import licence to customs release, see importing branded medicines from India: the licensed route.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside bimatoprost.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for bimatoprost.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Bimatoprost supply, the specific questions.
Does a generic version of Lumigan exist?
Yes. FDA-approved generic bimatoprost ophthalmic solution is registered and marketed in the US in both 0.03% and 0.01% concentrations from multiple manufacturers, and licensed generic bimatoprost eye drops are also available in the UK and EU alongside the Lumigan brand. Registration status varies by destination country, so M Care checks local approval before quoting brand or generic against a specific tender.
What is bimatoprost licensed to treat?
Both the FDA label and the UK/EU SmPC license bimatoprost for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, dosed as one drop in the affected eye once daily in the evening. A separate 0.03% bimatoprost product, marketed as Latisse, is licensed for eyelash hypotrichosis, a distinct indication with its own patient information leaflet.
What strengths of bimatoprost does M Care supply?
Lumigan and generic bimatoprost ophthalmic solution in 0.03% and 0.01% concentrations, matching the originator formulations. Tell us your formulary's preferred strength and destination-market registration status and we quote accordingly.
Does bimatoprost need cold-chain handling?
No. Bimatoprost eye drops store at room temperature and travel on standard ambient logistics. The UK SmPC gives a two-year unopened shelf life with a four-week in-use limit once a bottle is opened, which formulary planning should build into pack-size and reorder decisions.
Is bimatoprost on the WHO Essential Medicines List?
No. Bimatoprost does not appear on the WHO Model List of Essential Medicines; timolol is the topical antiglaucoma agent WHO lists in that category. Tender desks typically specify bimatoprost as a formulary-specific prostamide option rather than an EML first-line glaucoma drop.
What side effects should a dispensing pharmacist flag to patients?
Permanent darkening of the iris and reversible increases in eyelash length, thickness and pigmentation, plus periorbital tissue pigmentation change, are expected with long-term bimatoprost use and should be raised before treatment starts, particularly if only one eye is being treated. Safety and efficacy in children and adolescents under 18 years have not been established, so paediatric use sits outside the licensed population.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-19.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.